This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Q4 Earnings Meet Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?
by Zacks Equity Research
TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
by Harshit Gupta
DexCom stock shines with strong fourth quarter and full-year 2024 preliminary results, driven by innovation and global expansion. Explore if it's a buy or hold for your portfolio!
5 Stocks to Watch for Earnings This Week
by Tracey Ryniec
Zacks Stock Strategist, Tracey Ryniec, discusses 5 stock charts, including Netflix.
HAE or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. ABT: Which Stock Is the Better Value Option?
Abbott Stock Ahead of Q4 Earnings Results: Smart Buy or Risky Move?
by Urmimala Biswas
Abbott's Diagnostics arm is expected to have been driven by the widespread adoption of its top-tier systems and high testing demand in the fourth quarter.
TMDX Stock Down Despite Responding to Misleading Short-Seller Report
by Zacks Equity Research
TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
by Zacks Equity Research
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
by Zacks Equity Research
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Reasons to Add GE HealthCare Stock to Your Portfolio Now
by Zacks Equity Research
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GEHC Stock Gains on Long-Term Collaboration With Sutter Health
by Zacks Equity Research
GE HealthCare announces a seven-year strategic collaboration with Sutter Health.
BLS Data Shows Slowdown in Core CPI: Time to Buy MDT Stock Now?
by Urmimala Biswas
Medtronic's strong liquidity position should allow it to meet its near-term debt obligations.
Cardinal Health Stock May Gain With New Texas Distribution Center
by Zacks Equity Research
CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
Unlocking Q4 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Abbott (ABT) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Intuitive Surgical Stock Surges on Q4 Preliminary Revenue Beat
by Zacks Equity Research
ISRG records significant growth in the top line, driven by higher system placements as well as improved pricing. Procedure volume remains strong.
Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand
by Zacks Equity Research
NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
by Zacks Equity Research
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
M&A Synergies Drive BSX: Is it Worth Buying the Stock Now?
by Urmimala Biswas
Boston Scientific's recent acquisitions have added numerous products with immense potential.
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes
by Zacks Equity Research
With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
by Zacks Equity Research
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
GKOS Stock Gains Following Positive Study Data on iDose Platform
by Zacks Equity Research
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
NEOG Prelim Q2 Earnings Meet, '25 Sales View Down, Stock Falls
by Zacks Equity Research
NEOG's Food Safety business witnesses a slight year-over-year decrease in revenues for the second quarter of fiscal 2025.
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
by Zacks Equity Research
Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.